论文部分内容阅读
作者以13名既往无流行性感冒感染史的婴幼儿(年龄9个月至2岁)为研究对象,对注射精制纯化流行性感冒病毒A/Aichi/2/68(H_3N_2)疫苗的反应和血清学应答作了一系列观察。这种新疫苗系通过连续超速离心制成,经电子显微镜检查证实,其纯化度很高,无病毒凝块。蛋白质浓度仅165微克/毫升(含1714鸡细胞凝集单位病毒)或96微克/1000鸡细胞凝集单位病毒,提示均系病毒蛋白,无卵蛋白;热原试验阴性,内毒素含量仅0.16微克/毫升。13名婴幼儿的疫苗注射部位均在上臂,6名肌注,7名皮下注射。为防止其毒性,前4名剂量为340鸡细胞凝集单位,而其余9名则为500鸡细胞凝集单位。凡肌注的均出现发热反应,其中1例高达40℃。但注射部位皆无硬结或红斑等局部反应。皮下注射的均口服水杨酸盐预防,也均无局部反应;仅3名发热,其中1名体温高达40℃,且出现全身性惊厥。经检查未发现继发感染或其他发热原因。观察结果表
In this study, 13 infants and young children aged 9 months to 2 years who had no prior history of influenza infection were enrolled in this study. The response to the A / Aichi / 2/68 (H_3N_2) vaccine injected with purified purified influenza virus and the serum Learning response made a series of observations. The new vaccine, made by continuous ultracentrifugation, confirmed by electron microscopy that it is highly purified and free from viral clots. Protein concentration of only 165 micrograms / ml (including 1714 chicken cell agglutination unit virus) or 96 micrograms / 1000 chicken agglutination unit virus, suggesting that all the virus protein, egg-free protein; pyrogen test negative endotoxin content of only 0.16 micrograms / milliliter . Thirteen infants were injected in the upper arm, 6 intramuscularly and 7 subcutaneously. To prevent their toxicity, the first four doses were 340 chick cell agglutination units, while the remaining nine were 500 chick cell agglutination units. Where the intramuscular injection were fever, in which 1 case up to 40 ℃. However, injection sites are not induration or erythema and other local reactions. Subcutaneous injection of oral salicylate prevention, but also no local reaction; only three fever, of which 1 body temperature up to 40 ℃, and the emergence of generalized convulsions. After examination found no secondary infection or other causes of fever. Observation results table